Bio-Rad Laboratories Inc recently received approval from the US Food and Drug Administration (FDA) for its new Multispot HIV-1/HIV-2 rapid test. This highly sensitive test is expected to significantly aid in the diagnosis of HIV-1/HIV-2 (Human Immunodeficiency Virus, Types 1 and 2).
“This unique rapid test is the only single-use assay to be approved by the FDA for the detection and differentiation of HIV-1 and HIV-2 antibodies,” says John Goetz, Bio-Rad vice president and group manager of clinical diagnostics.
Bio-Rad’s product line includes a full range of kits for screening, confirmation, and differentiation of HIV-1 and HIV-2 antibodies. The new single-use qualitative enzyme immunoassay can be used on both fresh and frozen serum and plasma samples. It provides results in 10 minutes. The assay is also suitable for use in multi-test algorithms designed for statistical validation of rapid HIV test results. The Multispot HIV-1/HIV-2 rapid test is moderately complex and approved for use in CLIA-certified laboratories.
Bio-Rad Laboratories Inc
(800) 224-6723; www.bio-rad.com
